Edesa Biotech, Inc. 8-K

What Happened

• Edesa Biotech, Inc. (EDSA) announced on June 10, 2026 that it entered into a Securities Purchase Agreement for a private placement with certain investors. The company expects the closing on June 15, 2026, subject to customary conditions. Purchasers will buy an aggregate of 729,241 common shares for approximately $3.5 million in total. The company also entered a Registration Rights Agreement requiring it to file registration statements for resale of the shares within 45 days after the closing. The company issued a press release on June 11, 2026 announcing the transaction.

Key Details

• Aggregate shares to be sold: 729,241 common shares.
• Aggregate purchase price: approximately $3.5 million.
• Purchase price per share: $4.69 for investors other than the CEO; $5.21 per share for the CEO.
• Expected closing date: June 15, 2026 (subject to customary closing conditions).
• Registration: Company must file registration statement(s) within 45 days after closing and cause them to become effective within specified timeframes; both parties have customary indemnification rights.

Why It Matters

• The deal provides near-term funding for Edesa’s clinical programs and operations: the company stated proceeds will be used to advance its vitiligo program and paridiprubart drug candidate, and for working capital and general corporate purposes. For investors, the private placement dilutes existing shares but strengthens the company’s cash runway to support development milestones. The registration-rights agreement is intended to allow resale of the newly issued shares after the company files and the SEC clears the registration statement.